Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Start price
12.04.24
/
50%
€851.20
Target price
12.04.25
€676.58
Performance (%)
-2.11%
Price
29.04.24
€833.20
Summary
This prediction is currently active. With a performance of -2.11%, the SELL prediction for Regeneron Pharmaceuticals Inc. by Bank_of_America_Co_ is down slightly. This prediction currently runs until 12.04.25. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | -1.396% |
| iShares Core DAX® | 0.961% |
| iShares Nasdaq 100 | 2.626% |
| iShares Nikkei 225® | 0.217% |
| iShares S&P 500 | 1.540% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Bank of America Co. from $710.00 to $720.00. They now have an "underperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€756.00
29.03.23
29.03.23
€599.43
29.03.24
29.03.24
19.37%
30.03.24
30.03.24
